ATP13A5-AS1

Across TCGA pan-cancer cohorts, ATP13A5-AS1 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated ATP13A5-AS1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ATP13A5-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP13A5-AS1 expression acts as an unfavorable survival marker, although some lineages such as PAAD and UCS show a favorable association.

LIHC, UCEC, and PAAD are the cancer types where ATP13A5-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.207	0.567	<.001	72	view →
UCEC	DFS	Quartile	All	0.506	0.730	.001	54	view →
PAAD	OS	Tertile	All	0.669	0.341	.004	39	view →
BRCA	OS	Median	III,IV	0.437	0.618	.003	37	view →
STAD	DFS	Tertile	All	0.395	0.570	.010	36	view →
LGG	OS	Median	All	0.753	0.870	<.001	34	view →
UCS	DFS	Median	II,III,IV	0.528	0.159	.012	30	view →
BLCA	OS	Tertile	All	0.137	0.411	.013	30	view →
MESO	OS	Tertile	IV	0.265	0.647	.020	27	view →
READ	DFS	Tertile	All	0.233	0.730	.015	27	view →
ACC	DFS	Tertile	II,III,IV	0.646	0.165	.005	26	view →
LUSC	OS	Median	All	0.828	0.726	<.001	25	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

ATP13A5-AS1–LIHC (DFS)

Open the LIHC breakdown →